Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
RASH
MCID: EXN002
MIFTS: 62

Exanthem (RASH)

Categories: Infectious diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Exanthem

About this section

MalaCards integrated aliases for Exanthem:

Name: Exanthem 12 15 17
Exanthema 12 45
Rash 12 15
Rashes 44

Classifications:

MalaCards categories:
Global: Infectious diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:0050486
ICD9CM 36 782.1
MeSH 45 D005076
SNOMED-CT 69 1806006
ICD10 34 R21
UMLS 74 C0015230
Sources

Summaries for Exanthem

About this section
MedlinePlus : 44 A rash is an area of irritated or swollen skin. Many rashes are itchy, red, painful, and irritated. Some rashes can also lead to blisters or patches of raw skin. Rashes are a symptom of many different medical problems. Other causes include irritating substances and allergies. Certain genes can make people more likely to get rashes. Contact dermatitis is a common type of rash. It causes redness, itching, and sometimes small bumps. You get the rash where you have touched an irritant, such as a chemical, or something you are allergic to, like poison ivy. Some rashes develop right away. Others form over several days. Although most rashes clear up fairly quickly, others are long-lasting and need long-term treatment. Because rashes can be caused by many different things, it's important to figure out what kind you have before you treat it. If it is a bad rash, if it does not go away, or if you have other symptoms, you should see your health care provider. Treatments may include moisturizers, lotions, baths, cortisone creams that relieve swelling, and antihistamines, which relieve itching.

MalaCards based summary : Exanthem, also known as exanthema, is related to meningitis and aseptic meningitis. An important gene associated with Exanthem is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Irinotecan and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A skin disease that is characterized by a rash that results from a variety of causes including bacteria, viruses, toxins, drugs and autoimmune disorders.

Wikipedia : 77 An exanthem is a widespread rash usually occurring in children. An exanthem can be caused by toxins,... more...

Sources

Related Diseases for Exanthem

About this section

Diseases in the Exanthem family:

Bacterial Exanthem Viral Exanthem

Diseases related to Exanthem via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 meningitis 30.8 CRP NLRP3 TNF
2 aseptic meningitis 30.7 IL1RN NLRP3 TNF
3 drug reaction with eosinophilia and systemic symptoms 30.6 CRP TNF
4 mumps 30.0 IL2 TNF TNFRSF1A
5 brucellosis 29.9 CRP IL1RN IL2 TNF
6 pericarditis 29.8 CRP IL1RN TNF TNFRSF1A
7 myeloma, multiple 29.7 CRP HRAS IL2 KRAS TNF
8 leukemia, acute myeloid 29.3 HRAS IL2 KRAS MAP2K7 MTOR TNF
9 exanthema subitum 12.5
10 bacterial exanthem 12.4
11 viral exanthem 12.3
12 severe cutaneous adverse reaction 11.5
13 hand, foot and mouth disease 11.5
14 contagious pustular dermatitis 11.1
15 breast intraductal proliferative lesion 10.5 EGFR ERBB2
16 sigmoid neoplasm 10.4 HRAS KRAS
17 cryopyrin-associated periodic syndrome 10.4 CRP IL1RN NLRP3
18 schnitzler syndrome 10.4 CRP IL1RN NLRP3
19 apocrine adenoma 10.4 HRAS KRAS
20 hyperglobulinemic purpura 10.4 HSPG2 TRIM21
21 lung benign neoplasm 10.4 EGFR HRAS KRAS
22 pericardium disease 10.3 CRP IL1RN TRIM21
23 vulvar vestibulitis syndrome 10.3 IL1RN NLRP3 TNF
24 oral tuberculosis 10.3 IL2 TNF
25 anal canal adenocarcinoma 10.3 HRAS KRAS TNFRSF1B
26 luminal breast carcinoma 10.3 EGFR ERBB2 MTOR
27 ovary adenocarcinoma 10.3 ERBB2 HRAS KRAS
28 measles 10.3
29 malignant ovarian surface epithelial-stromal neoplasm 10.3 ERBB2 HRAS KRAS
30 colonic disease 10.3 EGFR HRAS KRAS
31 ovary epithelial cancer 10.3 ERBB2 HRAS KRAS
32 colorectal adenocarcinoma 10.3 EGFR HRAS KRAS
33 juvenile ankylosing spondylitis 10.3 IL1RN TNF TNFRSF1B
34 scrub typhus 10.3 CRP GPT TNF
35 colorectal adenoma 10.3 CRP HRAS KRAS
36 scleral disease 10.3 IL1RN TNF TNFRSF1B
37 pustulosis of palm and sole 10.3 IL1RN TNF TNFRSF1B
38 progesterone-receptor negative breast cancer 10.3 EGFR ERBB2
39 temporal arteritis 10.3 CRP IL1RN TNF
40 estrogen-receptor positive breast cancer 10.3 EGFR ERBB2 MTOR
41 carcinosarcoma 10.3 ERBB2 HRAS KRAS
42 obstructive jaundice 10.3 CRP GPT TNF
43 chorioamnionitis 10.3 CRP IL1RN TNF
44 arthropathy 10.3 CRP NLRP3 TNF
45 differentiated thyroid carcinoma 10.3 EGFR HRAS KRAS
46 endometrial adenocarcinoma 10.3 EGFR ERBB2 KRAS
47 geographic tongue 10.3 EGFR MTOR TNF
48 mucinous lung adenocarcinoma 10.3 EGFR ERBB2 HRAS KRAS
49 adenosquamous lung carcinoma 10.3 EGFR ERBB2 HRAS KRAS
50 hyper-igd syndrome 10.3 CRP IL1RN TNFRSF1A

Graphical network of the top 20 diseases related to Exanthem:



Diseases related to Exanthem
Sources

Symptoms & Phenotypes for Exanthem

About this section

GenomeRNAi Phenotypes related to Exanthem according to GeneCards Suite gene sharing:

27 (show all 20)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.59 EGFR HRAS KRAS MTOR KALRN
2 Decreased viability GR00106-A-0 10.59 KRAS
3 Decreased viability GR00221-A-1 10.59 EGFR HRAS KRAS MAP2K7 MTOR
4 Decreased viability GR00221-A-2 10.59 HRAS KRAS
5 Decreased viability GR00221-A-3 10.59 HRAS
6 Decreased viability GR00221-A-4 10.59 EGFR MTOR
7 Decreased viability GR00301-A 10.59 KRAS KALRN
8 Decreased viability GR00342-S-1 10.59 MAP2K7 MTOR KALRN
9 Decreased viability GR00342-S-2 10.59 MTOR KALRN
10 Decreased viability GR00342-S-3 10.59 KALRN
11 Decreased viability GR00381-A-1 10.59 KRAS KALRN
12 Decreased viability GR00402-S-2 10.59 EGFR HRAS KRAS MAP2K7 MTOR KALRN
13 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 EGFR ERBB2 HRAS HSPG2 KALRN MTOR
14 Decreased cell migration GR00055-A-1 9.77 EGFR HRAS KALRN KRAS MTOR
15 Decreased viability with paclitaxel GR00179-A-1 9.7 EGFR MTOR ERBB2
16 Decreased viability with paclitaxel GR00179-A-2 9.7 MTOR
17 Decreased viability with paclitaxel GR00179-A-3 9.7 EGFR MTOR
18 Decreased substrate adherent cell growth GR00193-A-2 9.65 EGFR KALRN MAP2K7 MTOR
19 Decreased substrate adherent cell growth GR00193-A-3 9.65 MAP2K7
20 Increased cell migration GR00055-A-3 8.92 EGFR HRAS KRAS MTOR

MGI Mouse Phenotypes related to Exanthem:

47 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.49 ACE CRP EGFR ERBB2 HRAS HSPG2
2 cardiovascular system MP:0005385 10.46 ACE CRP EGFR ERBB2 HRAS HSPG2
3 growth/size/body region MP:0005378 10.42 ACE EGFR ERBB2 HRAS HSPG2 IL1RN
4 behavior/neurological MP:0005386 10.4 ACE ERBB2 HRAS HSPG2 IL2 KALRN
5 mortality/aging MP:0010768 10.4 ACE EGFR ERBB2 HRAS HSPG2 IL1RN
6 cellular MP:0005384 10.38 EGFR ERBB2 HSPG2 IL1RN IL2 KRAS
7 endocrine/exocrine gland MP:0005379 10.36 ACE EGFR ERBB2 HRAS IL2 KALRN
8 immune system MP:0005387 10.36 ACE CRP EGFR HSPG2 IL1RN IL2
9 hematopoietic system MP:0005397 10.35 ACE EGFR HSPG2 IL1RN IL2 KRAS
10 integument MP:0010771 10.35 EGFR ERBB2 HRAS HSPG2 IL1RN KALRN
11 digestive/alimentary MP:0005381 10.29 EGFR ERBB2 HRAS HSPG2 IL2 KRAS
12 nervous system MP:0003631 10.21 EGFR ERBB2 HRAS HSPG2 KALRN KRAS
13 craniofacial MP:0005382 10.2 EGFR ERBB2 HRAS HSPG2 KRAS TNF
14 liver/biliary system MP:0005370 10.16 ACE EGFR HSPG2 IL2 KRAS NLRP3
15 neoplasm MP:0002006 10.16 ACE EGFR ERBB2 HRAS IL2 KRAS
16 muscle MP:0005369 10.13 EGFR ERBB2 HSPG2 KALRN KRAS MTOR
17 limbs/digits/tail MP:0005371 10.07 EGFR ERBB2 HSPG2 KRAS NLRP3 TNF
18 normal MP:0002873 10.02 EGFR ERBB2 HRAS KALRN KRAS MAP2K7
19 no phenotypic analysis MP:0003012 10.01 EGFR HRAS IL2 KALRN KRAS MTOR
20 reproductive system MP:0005389 10 ACE EGFR ERBB2 IL1RN IL2 KALRN
21 renal/urinary system MP:0005367 9.97 ACE EGFR HRAS KRAS MTOR NLRP3
22 respiratory system MP:0005388 9.85 EGFR ERBB2 HRAS HSPG2 IL2 KRAS
23 skeleton MP:0005390 9.73 EGFR ERBB2 GPT HRAS HSPG2 IL1RN
24 vision/eye MP:0005391 9.23 EGFR HSPG2 IL2 KRAS MAP2K7 TNF
Sources

Drugs & Therapeutics for Exanthem

About this section

Drugs for Exanthem (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1280)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
2
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
3
Cetuximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 205923-56-4 56842117 2333
4
Phylloquinone Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 84-80-0
5
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1 51-21-8 3385
6
Petrolatum Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 8009-03-8
7
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-66-6 32051
8
Menthol Approved Phase 4,Phase 3 2216-51-5 16666
9
Zinc oxide Approved Phase 4,Phase 3,Not Applicable 1314-13-2
10
Vancomycin Approved Phase 4,Phase 3,Not Applicable 1404-90-6 441141 14969
11
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 124-94-7 31307
12
Mupirocin Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 12650-69-0 446596
13
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 55-56-1 2713 9552079
14
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 69-72-7 338
15
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
16
Sulbactam Approved Phase 4,Phase 2 68373-14-8
17
Piperacillin Approved Phase 4,Not Applicable 66258-76-2 43672
18
Sulfadoxine Approved, Investigational Phase 4,Phase 1,Phase 2 2447-57-6 17134
19
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 58-14-0 4993
20
Azithromycin Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 83905-01-5 55185 447043
21
Latanoprost Approved, Investigational Phase 4 130209-82-4 5311221 5282380
22
Ketorolac Approved Phase 4,Not Applicable 66635-83-4, 74103-06-3 3826
23
Travoprost Approved Phase 4 157283-68-6 5282226
24
Iron Approved, Experimental Phase 4,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 23925 27284
25
Ferrous fumarate Approved Phase 4 141-01-5
26
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
27
Cefazolin Approved Phase 4,Phase 3,Not Applicable 25953-19-9 656510 33255
28
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
29
Ketotifen Approved Phase 4,Phase 3 34580-14-8, 34580-13-7 3827
30
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-45-6 774
31
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 94-36-0 7187
32
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 18323-44-9 29029
33
Ranibizumab Approved Phase 4,Phase 3,Phase 1,Phase 2 347396-82-1 459903
34 Pinaverium Approved Phase 4 59995-65-2
35
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
36
Tazobactam Approved Phase 4 89786-04-9 123630
37
Cefuroxime Approved Phase 4,Phase 2,Not Applicable 55268-75-2 5361202 5479529
38
Clarithromycin Approved Phase 4,Not Applicable 81103-11-9 84029
39
Ciprofloxacin Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 85721-33-1 2764
40
Moxifloxacin Approved, Investigational Phase 4,Phase 1 354812-41-2, 151096-09-2 152946
41
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
42 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7681-49-4
43
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53-03-2 5865
44
Nevirapine Approved Phase 4,Phase 3,Phase 2 129618-40-2 4463
45
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 134678-17-4 60825
46
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 22916-47-8 4189
47
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492 6473866
48
Nicotine Approved Phase 4,Phase 3,Not Applicable 54-11-5 942 89594
49
Caffeine Approved Phase 4,Phase 2,Phase 1,Not Applicable 58-08-2 2519
50
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 557795-19-4, 341031-54-7 5329102

Interventional clinical trials:

(show top 50) (show all 3297)
# Name Status NCT ID Phase Drugs
1 Elmex Gel Efficacy in Preventing White Spot Lesions Unknown status NCT00268138 Phase 4 elmex gel
2 FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema Unknown status NCT01315990 Phase 4 FOLFIRI + Cetuximab
3 Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants Unknown status NCT02716415 Phase 4 Calmoseptine Ointment;Destin Maximum Strength 40% Zinc
4 Line Versus Spot Ablation in Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
5 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
6 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
7 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Unknown status NCT01753401 Phase 4 Acthar;Placebo for Acthar
8 Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection Unknown status NCT02547103 Phase 4
9 Effectiveness and Economic Evaluation of Glass Ionomer Material Using as Dental Sealant Unknown status NCT03034837 Phase 4 resin sealant;ART sealant
10 Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox Unknown status NCT02383797 Phase 4
11 A Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
12 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
13 Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome Unknown status NCT02424695 Phase 4 Gabapentin Enacarbil (GEn);Placebo
14 Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old Unknown status NCT02806531 Phase 4
15 Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
16 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
17 A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women Unknown status NCT02575755 Phase 4 Azithromycin plus piperaquine phosphate;Sulfadoxine-pyrimethamine
18 The Laser in Pseudoexfoliation (LIP) Study Unknown status NCT01704989 Phase 4 Prostagladin
19 Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Unknown status NCT02796560 Phase 4 Brand name travoprost;Generic travoprost
20 The Use of Iron Therapy for Patients With Anemia After Surgery Unknown status NCT01975272 Phase 4 Ferinject;Ferrous fumarate;Placebo for ferrous fumarate;Placebo for ferinject
21 Kunxian for the Treatment of Rheumatoid Arthritis Unknown status NCT02764515 Phase 4 Kunxian Capsule;Methotrexate
22 The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection Unknown status NCT02307006 Phase 4 Ceftaroline;Cefazolin / Vancomycin
23 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
24 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
25 A Study Comparing Combination Clindamycin Phosphate/Tretinoin Gel Alone Versus With Benzoyl Peroxide Foaming Cloths for Facial Acne Unknown status NCT01422785 Phase 4 clindamycin phosphate 1.2%/tretinoin 0.025% gel alone;clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths
26 Clinical Study to Evaluate the Efficacy of Topical Medications Containing Benzoyl Peroxide and Sulfur in the Regression in the Short Time (24 Hours) of Moderate Acne Vulgaris Grade II (Pimples) Unknown status NCT01260571 Phase 4 Benzoyl peroxide and sulfur
27 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
28 Skin Changes in Head and Neck Cancer During Immuno-(Chemo-) And Radiotherapy With Erbitux® (HICARE) Unknown status NCT01553032 Phase 4 Erbitux®
29 Targeted Indoor Residual Spraying Against Malaria Unknown status NCT02556242 Phase 4
30 Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction Unknown status NCT02833103 Phase 4 Danshu Capsules;Pinaverium Bromide
31 Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections Unknown status NCT02171338 Phase 4
32 Determination of Safety and Consumers' Satisfaction of Moussik Versus Desitin Creamy Ointment in Diaper Rash Prophylaxis Withdrawn NCT01167465 Phase 4
33 Clinical Study to Evaluate the Efficacy and Safety of Two Marketed Investigational Products in Children With Diaper Rash Completed NCT00219466 Phase 4
34 Golimumab Dried Blood Spot Analysis Active, not recruiting NCT02910375 Phase 4
35 The Effectiveness of Resin-Modified Glass Ionomer Varnish in Preventing White Spot Lesions During Fixed Appliance Orthodontic Therapy Not yet recruiting NCT03711097 Phase 4 Vanish XT Dental Varnish
36 Treatment of Postorthodontic White Spot Lesions Recruiting NCT03217084 Phase 4 MI varnish GC;White varnish 3M
37 Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug) Withdrawn NCT01299220 Phase 4 Acitretin
38 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
39 Reminerlization Potential of Innovative Biomimetic Material in Caries White Spot Lesions Recruiting NCT03823612 Phase 4 Clinpro Tooth Creme;GC tooth mousse
40 MI Varnish for the Prevention of White Spot Lesions Completed NCT03446690 Phase 4 MI Varnish
41 Remineralisation of White Spot Lesions by Elmex® gelée in Post-orthodontic Patients Completed NCT01329731 Phase 4 elmex® gelée;negative control (placebo)
42 Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients Completed NCT02184299 Phase 4 Nevirapine;Prednisone
43 Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot Completed NCT02742285 Phase 4 Artemether + lumefantrine
44 Therapeutic Effect of Two Fluoride Varnishes on White Spot Lesions: a Clinical Study Completed NCT00723515 Phase 4 sodium fluoride;sodium fluoride calcium fluoride
45 MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study Completed NCT02424097 Phase 4 CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste;1,100pm F-toothpaste and 0.5%NaF rinse
46 Efficacy of Handheld Acne Heat Device Withdrawn NCT01613924 Phase 4
47 Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients Completed NCT01768390 Phase 4
48 Genotype Based Personalized Prescription of Nevirapine Completed NCT00986063 Phase 4
49 Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Completed NCT02131220 Phase 4 Prourokinase;Tirofiban;normal saline
50 Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots Completed NCT01149876 Phase 4 Tretinoin cream 0.05

Search NIH Clinical Center for Exanthem

Cochrane evidence based reviews: exanthema

Sources

Genetic Tests for Exanthem

About this section
Sources

Anatomical Context for Exanthem

About this section

MalaCards organs/tissues related to Exanthem:

42
Skin, Eye, Testes, Breast, Kidney, Bone, Brain
Sources

Publications for Exanthem

About this section

Articles related to Exanthem:

(show top 50) (show all 499)
# Title Authors Year
1
Targetoid skin lesions following a Christmas tree pattern: viral or paraviral exanthem? ( 30734719 )
2019
2
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by mefenamic acid. ( 30581942 )
2019
3
Varenicline-induced symmetrical drug-related intertriginous and flexural exanthema. ( 30719986 )
2019
4
Unilateral Laterothoracic Exanthema: An Underrecognized, Innocuous Entity. ( 30789038 )
2019
5
Exanthema associated with Capnocytophaga canimorsus bacteremia. ( 30877041 )
2019
6
Ten-year-old traveller with fever and an exceptional exanthem. ( 29314384 )
2018
7
Acral-accentuated exanthem in an infant with parechovirus meningitis. ( 29205494 )
2018
8
What's in a Rash? Viral Exanthem Versus CBRNE Exposure: Teleconsultation Support for Two Special Forces Soldiers With Diffuse Rash in an Austere Environment. ( 29889970 )
2018
9
Asymmetric periflexural exanthem: not a distinctive disease of childhood. ( 29582621 )
2018
10
Ten-year-old traveller with fever and an exceptional exanthem. ( 29314380 )
2018
11
50 Years Ago in The Journal of Pediatrics: Atypical Exanthem after Exposure to Natural Measles: Eleven Cases in Children Previously Inoculated with Killed Vaccine. ( 29389454 )
2018
12
Exanthem, Fieber und Arthralgien bei einer 19-jAohrigen Patientin. ( 29645383 )
2018
13
Eosinophilia, pruritic exanthema and digital necrosis. ( 28624075 )
2018
14
Infant with exanthema and fever. ( 27876188 )
2018
15
Immunohistochemical Demonstration of Parvovirus B19 Viral Protein 2 in Periflexural Exanthema in an Adult, Supporting Antibody-Dependent Enhancement as Means of Endothelial Uptake of the Virus. ( 28700372 )
2018
16
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. ( 29288229 )
2018
17
A 62-Year-Old Woman With Fever and Exanthema. ( 29521699 )
2018
18
Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients. ( 29546073 )
2018
19
Overlap Between DRESS Syndrome and Exanthema Induced by Sulfadiazine in a Patient Treated With Sulfamethoxazole: Utility of the Lymphocyte Transformation Test for Identification of the Culprit Drug. ( 29661742 )
2018
20
Tacrolimus-induced symmetric drug-related intertriginous and flexural exanthema (SDRIFE). ( 29722025 )
2018
21
Clindamycin-induced Maculopapular Exanthema with Preferential Involvement of Striae Distensae: A Koebner phenomenon? ( 29782303 )
2018
22
First case of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) due to Berberine, an over-the-counter herbal glycemic control agent. ( 29808929 )
2018
23
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature. ( 30062790 )
2018
24
Palmoplantar exanthema and liver dysfunction. ( 30102597 )
2018
25
Diffuse maculopapular exanthema and a positive lymphocyte transformation test reaction in response to clarithromycin. ( 30159155 )
2018
26
Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. ( 30323078 )
2018
27
From known to the unknown: investigating an unusual outbreak of viral exanthema in a secondary school in Abeokuta, Nigeria, 2015. ( 30858910 )
2018
28
Unilateral laterothoracic exanthem. ( 28754336 )
2017
29
Can Unilateral Pityriasis Rosea be Considered a Form of Superimposed Lateralized Exanthem? ( 28764276 )
2017
30
TherapierefraktAores Exanthem eines sechs Monate alten SAouglings. ( 29228485 )
2017
31
Superimposed lateralized exanthem in a 30-year-old woman. ( 28893877 )
2017
32
Image Gallery: Flagellate bullous exanthem in chikungunya. ( 29052889 )
2017
33
Epstein-Barr virus exanthem in an adult patient with myelodysplastic syndrome. ( 29274098 )
2017
34
Exanthem und Ekzem bei einem anderthalbjAohrigen Jungen. ( 28214315 )
2017
35
Dengue-Fieber und die Differenzialdiagnosen zu Exanthem, Fieber und Kopfschmerzen nach Fernreise. ( 28140551 )
2017
36
IgA multiple myeloma in a patient with an IgG pemphigus foliaceus-like exanthem. ( 28856664 )
2017
37
Assessment of histopathological features of maculopapular viral exanthem and drug-induced exanthem. ( 28914958 )
2017
38
Acute localized exanthem due to Coxsackievirus A4. ( 28956547 )
2017
39
Drug-specific CD4+ T-cell immune responses are responsible for antituberculosis drug-induced maculopapular exanthema and drug reaction with eosinophilia and systemic symptoms syndrome. ( 27373553 )
2017
40
Exanthema, fever and arthralgia in a pregnant woman. ( 26493355 )
2017
41
Fixed exanthema emerged following narrowband ultraviolet B irradiation. ( 27543011 )
2017
42
Occurrence of equine coital exanthema (ECE) in stallions in Japan and effectiveness of treatment with valacyclovir for ECE. ( 28123140 )
2017
43
Isolation of equine herpesvirus 3 (EHV-3) from equine coital exanthema of two stallions and sero-epidemiology of EHV-3 infection in Japan. ( 28132964 )
2017
44
Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by golimumab. ( 28217835 )
2017
45
Symmetrical drug-related intertriginous and flexural exanthema possibly due to thiamine disulfide. ( 28225167 )
2017
46
Main Characteristics of Zika Virus Exanthema in Guadeloupe. ( 28241170 )
2017
47
Pustulobullous variant of SDRIFE (symmetrical drug-related intertriginous and flexural exanthema). ( 28514083 )
2017
48
Pustulobullöse Variante eines SDRIFE (symmetrical drug-related intertriginous and flexural exanthema). ( 28591434 )
2017
49
Cutaneous Drug REactions: Annular, polycyclic erythematous exanthema in an oncology patient. ( 28677584 )
2017
50
Allergic Maculo-Papular Exanthema Due To Terbinafine. ( 28785353 )
2017
Sources

Variations for Exanthem

About this section
Sources

Expression for Exanthem

About this section
Search GEO for disease gene expression data for Exanthem.
Sources

Pathways for Exanthem

About this section

Pathways related to Exanthem according to GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.03 CRP EGFR ERBB2 HRAS IL1RN IL2
2
ERK Signaling 65
Show member pathways
 13.93 EGFR ERBB2 HRAS HSPG2 IL2 KRAS
3
PEDF Induced Signaling 65
Show member pathways
 13.72 EGFR ERBB2 HRAS IL1RN IL2 KRAS
4
TGF-Beta Pathway 65
Show member pathways
 13.6 EGFR ERBB2 HRAS IL2 KRAS MAP2K7
5
Akt Signaling 65
Show member pathways
 13.48 EGFR ERBB2 HRAS IL2 KRAS MTOR
6
Nanog in Mammalian ESC Pluripotency 65
Show member pathways
 13.35 EGFR ERBB2 HRAS IL2 KRAS TNF
7
PAK Pathway 65
Show member pathways
 13.34 EGFR ERBB2 HRAS IL2 KRAS MAP2K7
8
Cytokine Signaling in Immune system 67
Show member pathways
 13.27 EGFR ERBB2 HRAS IL1RN IL2 KRAS
9
Toll-like Receptor Signaling Pathway 38 1
Show member pathways
 13.25 ACE IL2 MAP2K7 NLRP3 TNF TNFRSF1A
10
IL-2 Pathway 65
Show member pathways
 13.23 EGFR ERBB2 HRAS IL2 KRAS MAP2K7
11
Phospholipase-C Pathway 65
Show member pathways
 13.13 EGFR HRAS HSPG2 IL2 KRAS MTOR
12
p70S6K Signaling 65
Show member pathways
 13.12 ACE EGFR HRAS IL2 KRAS MTOR
13
TNFR1 Pathway 65
Show member pathways
 13 EGFR HRAS KRAS MAP2K7 MTOR TNF
14
Development Angiotensin activation of ERK 23
Show member pathways
 12.99 EGFR HRAS KRAS TNF TNFRSF1A TNFRSF1B
15
NFAT and Cardiac Hypertrophy 65
Show member pathways
 12.95 EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
16
PI3K-Akt signaling pathway 38
Show member pathways
 12.93 EGFR ERBB2 HRAS IL2 KRAS MTOR
17
Pathways in cancer 38
12.92 EGFR ERBB2 HRAS IL2 KRAS MTOR
18
Apoptosis Modulation and Signaling 1
Show member pathways
 12.87 HRAS KRAS TNF TNFRSF1A TNFRSF1B
19
Gastric cancer 38
Show member pathways
 12.83 EGFR ERBB2 HRAS KRAS MTOR
20
Human cytomegalovirus infection 38
Show member pathways
 12.82 EGFR HRAS HSPG2 KRAS MAP2K7 MTOR
21
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.8 EGFR ERBB2 HRAS KRAS MTOR
22
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 66
Show member pathways
 12.8 HRAS IL2 KRAS MTOR TNF TNFRSF1A
23
Development HGF signaling pathway 23
Show member pathways
 12.78 ERBB2 HRAS KRAS MAP2K7 MTOR
24
NF-KappaB Family Pathway 65
Show member pathways
 12.77 EGFR IL2 TNF TNFRSF1A TNFRSF1B
25
Glioma 38
Show member pathways
 12.75 EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
26
MAPK signaling pathway 1 38
12.75 EGFR ERBB2 HRAS KRAS MAP2K7 TNF
27
Development Endothelin-1/EDNRA signaling 23
Show member pathways
 12.74 EGFR HRAS KRAS MAP2K7 MTOR
28
Immune response NFAT in immune response 23
Show member pathways
 12.71 HRAS IL2 MAP2K7 TNF TNFRSF1A TNFRSF1B
29
TRAF Pathway 65
Show member pathways
 12.69 HRAS MAP2K7 TNF TNFRSF1A TNFRSF1B
30
Immune response IL-23 signaling pathway 23
Show member pathways
 12.66 EGFR ERBB2 HRAS IL2 KRAS TNF
31
Influenza A 38
Show member pathways
 12.65 IL2 MAP2K7 NLRP3 TNF TNFRSF1A
32
NF-kappaB Signaling 4
12.65 IL1RN IL2 TNF TNFRSF1A TNFRSF1B
33
ErbB signaling pathway 1 38
Show member pathways
 12.63 EGFR ERBB2 HRAS KRAS MAP2K7 MTOR
34
4-1BB Pathway 65
Show member pathways
 12.62 EGFR HRAS KRAS MAP2K7 TNF TNFRSF1A
35
MicroRNAs in cancer 38
12.6 EGFR ERBB2 HRAS KRAS MTOR
36
Prolactin Signaling Pathway 1 38
Show member pathways
 12.56 ERBB2 HRAS IL1RN KRAS MTOR
37
MET promotes cell motility 67
Show member pathways
 12.53 HRAS HSPG2 KRAS MTOR
38
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.49 EGFR HRAS IL2 KRAS MTOR
39
T cell receptor signaling pathway 38
Show member pathways
 12.49 HRAS IL2 KRAS MAP2K7 TNF
40
RANK Signaling in Osteoclasts 65
Show member pathways
 12.47 HRAS KRAS MAP2K7 MTOR
41
Phospholipase D signaling pathway 38
Show member pathways
 12.47 EGFR HRAS KRAS MTOR
42
Human T-cell leukemia virus 1 infection 38
12.42 HRAS IL2 KRAS TNF TNFRSF1A
43
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.41 EGFR ERBB2 HRAS IL2 KRAS MAP2K7
44
Apoptosis Pathway 73
Show member pathways
 12.41 EGFR ERBB2 HRAS IL2 KRAS MTOR
45
TNF signaling (REACTOME) 67
Show member pathways
 12.4 MAP2K7 TNF TNFRSF1A TNFRSF1B
46
Signaling by ERBB2 67
Show member pathways
 12.37 EGFR ERBB2 HRAS KRAS
47
G-protein signaling Ras family GTPases in kinase cascades (scheme) 23
Show member pathways
 12.32 HRAS KRAS MAP2K7 MTOR
48
VEGF Signaling Pathway 62 68
Show member pathways
 12.3 EGFR HRAS KRAS MAP2K7
49
IL-1 Family Signaling Pathways 66
Show member pathways
 12.3 EGFR HRAS IL1RN MAP2K7 TNF
50
C-type lectin receptor signaling pathway 38
Show member pathways
 12.29 HRAS IL2 KRAS NLRP3 TNF
Sources

GO Terms for Exanthem

About this section

Cellular components related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.91 ACE CRP EGFR GPT HSPG2 IL1RN
2 extracellular region GO:0005576 9.85 ACE CRP EGFR HSPG2 IL1RN IL2
3 membrane raft GO:0045121 9.02 EGFR KRAS TNF TNFRSF1A TNFRSF1B
4 tumor necrosis factor receptor superfamily complex GO:0002947 8.96 TNFRSF1A TNFRSF1B

Biological processes related to Exanthem according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.88 CRP ERBB2 HRAS KRAS MTOR TNF
2 positive regulation of protein kinase B signaling GO:0051897 9.87 EGFR ERBB2 MTOR TNF
3 cellular response to lipopolysaccharide GO:0071222 9.86 IL1RN NLRP3 TNF TNFRSF1B
4 cell surface receptor signaling pathway GO:0007166 9.85 EGFR ERBB2 HRAS TNFRSF1A TNFRSF1B
5 positive regulation of JNK cascade GO:0046330 9.84 HRAS IL1RN TNF
6 positive regulation of cell growth GO:0030307 9.84 EGFR ERBB2 IL2
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.83 EGFR HRAS TNF
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.81 TNF TNFRSF1A TNFRSF1B
9 response to glucocorticoid GO:0051384 9.81 IL1RN KRAS TNF
10 positive regulation of epithelial cell proliferation GO:0050679 9.8 EGFR ERBB2 HRAS
11 cytokine-mediated signaling pathway GO:0019221 9.8 IL1RN IL2 KRAS TNF TNFRSF1A TNFRSF1B
12 cellular response to growth factor stimulus GO:0071363 9.78 EGFR ERBB2 TNFRSF1B
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 EGFR MTOR TNF
14 cellular response to amino acid stimulus GO:0071230 9.77 EGFR MTOR TNF
15 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.75 TNF TNFRSF1A TNFRSF1B
16 negative regulation of inflammatory response GO:0050728 9.73 IL2 NLRP3 TNFRSF1A TNFRSF1B
17 MAPK cascade GO:0000165 9.73 EGFR ERBB2 HRAS IL2 KRAS TNF
18 positive regulation of interferon-gamma production GO:0032729 9.72 HRAS IL2 TNF
19 inflammatory response GO:0006954 9.7 CRP HSPG2 IL1RN NLRP3 TNF TNFRSF1A
20 positive regulation of inflammatory response GO:0050729 9.67 EGFR IL2 TNF TNFRSF1A
21 astrocyte activation GO:0048143 9.65 EGFR TNF
22 negative regulation of lipid storage GO:0010888 9.65 CRP TNF
23 positive regulation of ceramide biosynthetic process GO:2000304 9.64 TNF TNFRSF1A
24 death-inducing signaling complex assembly GO:0071550 9.63 TNF TNFRSF1A
25 regulation of establishment of endothelial barrier GO:1903140 9.62 TNF TNFRSF1A
26 response to isolation stress GO:0035900 9.61 HRAS KRAS
27 negative regulation of ERBB signaling pathway GO:1901185 9.58 EGFR ERBB2
28 aortic valve development GO:0003176 9.54 TNFRSF1A TNFRSF1B
29 negative regulation of extracellular matrix constituent secretion GO:0003332 9.51 TNFRSF1A TNFRSF1B
30 positive regulation of apoptotic process involved in morphogenesis GO:1902339 9.49 TNFRSF1A TNFRSF1B
31 pulmonary valve development GO:0003177 9.48 TNFRSF1A TNFRSF1B
32 positive regulation of transcription by RNA polymerase III GO:0045945 9.35 MTOR
33 positive regulation of MAP kinase activity GO:0043406 9.35 EGFR ERBB2 HRAS KRAS TNF
34 chronic inflammatory response to antigenic stimulus GO:0002439 9.22 TNF
35 positive regulation of protein phosphorylation GO:0001934 9.17 EGFR ERBB2 HRAS IL2 KRAS MTOR
36 signal transduction GO:0007165 10.27 EGFR ERBB2 HRAS KALRN KRAS MAP2K7

Molecular functions related to Exanthem according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.55 EGFR ERBB2 HRAS KRAS MTOR
2 protein phosphatase binding GO:0019903 9.5 EGFR ERBB2 MAP2K7
3 identical protein binding GO:0042802 9.5 CRP EGFR ERBB2 MTOR NLRP3 TNF
4 tumor necrosis factor-activated receptor activity GO:0005031 9.26 TNFRSF1A TNFRSF1B
5 tumor necrosis factor binding GO:0043120 8.62 TNFRSF1A TNFRSF1B
Sources

Sources for Exanthem

About this section
3 CDC
7 CNVD
9